Cargando…
The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance
BACKGROUND: Non-bismuth containing quadruple therapy (concomitant therapy) is an alternative treatment for Helicobacter pylori (H. pylori) eradication with increasing clarithromycin-resistant strains over times. This study compared the efficacies of non-bismuth containing quadruple therapy (concomit...
Autores principales: | Huang, Tzu-Hsin, Yang, Shih-Cheng, Tai, Wei-Chen, Liang, Chih-Ming, Kuo, Chung-Mou, Yao, Chih-Chien, Wu, Cheng-Kun, Kuo, Yuan-Hung, Chou, Yeh-Pin, Lee, Chen-Hsiang, Wu, Keng-Liang, Chuah, Seng-Kee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chang Gung University
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068570/ https://www.ncbi.nlm.nih.gov/pubmed/35292265 http://dx.doi.org/10.1016/j.bj.2020.11.012 |
Ejemplares similares
-
Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice
por: Hung, Kuo-Tung, et al.
Publicado: (2021) -
Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
por: Huang, Hsiang Tso, et al.
Publicado: (2018) -
A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial
por: Tai, Wei-Chen, et al.
Publicado: (2019) -
Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection
por: Jheng, Guang-Hong, et al.
Publicado: (2015) -
Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication
por: Tai, Wei-Chen, et al.
Publicado: (2015)